S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:CALT

Calliditas Therapeutics AB (publ) Stock Forecast, Price & News

$19.75
+1.09 (+5.84%)
(As of 01/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$19.04
$20.36
50-Day Range
$16.65
$26.32
52-Week Range
$14.22
$33.19
Volume
134,690 shs
Average Volume
46,599 shs
Market Capitalization
$516.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.14
30 days | 90 days | 365 days | Advanced Chart
Receive CALT News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.


Calliditas Therapeutics AB (publ) logo

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.

Headlines

Calliditas Therapeutics: Interim Report Q3, 2021
November 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALT
Fax
N/A
Employees
46
Year Founded
N/A

Sales & Book Value

Annual Sales
$90 thousand
Book Value
$5.71 per share

Profitability

Net Income
$-47.25 million
Pretax Margin
-235.90%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$516.88 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/17/2021
Today
1/28/2022
Next Earnings (Estimated)
2/17/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

890th out of 1,417 stocks

Pharmaceutical Preparations Industry

437th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Frequently Asked Questions

Is Calliditas Therapeutics AB (publ) a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Calliditas Therapeutics AB (publ) stock.
View analyst ratings for Calliditas Therapeutics AB (publ)
or view top-rated stocks.

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a increase in short interest in January. As of January 15th, there was short interest totaling 88,900 shares, an increase of 51.2% from the December 31st total of 58,800 shares. Based on an average daily volume of 178,400 shares, the days-to-cover ratio is currently 0.5 days.
View Calliditas Therapeutics AB (publ)'s Short Interest
.

When is Calliditas Therapeutics AB (publ)'s next earnings date?

Calliditas Therapeutics AB (publ) is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Calliditas Therapeutics AB (publ)
.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) posted its quarterly earnings data on Wednesday, November, 17th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.62. The company earned $22.92 million during the quarter. During the same period last year, the business posted ($0.62) EPS.
View Calliditas Therapeutics AB (publ)'s earnings history
.

What price target have analysts set for CALT?

3 analysts have issued 12-month target prices for Calliditas Therapeutics AB (publ)'s stock. Their forecasts range from $62.00 to $62.00. On average, they expect Calliditas Therapeutics AB (publ)'s share price to reach $62.00 in the next year. This suggests a possible upside of 213.9% from the stock's current price.
View analysts' price targets for Calliditas Therapeutics AB (publ)
or view top-rated stocks among Wall Street analysts.

Who are Calliditas Therapeutics AB (publ)'s key executives?

Calliditas Therapeutics AB (publ)'s management team includes the following people:
  • Ms. Renee Aguiar-Lucander, Chief Exec. Officer (Age 59)
  • Mr. Fredrik Johansson, Chief Financial Officer (Age 44)
  • Dr. Katayoun Welin-Berger Ph.D., VP of Operations (Age 53)
  • Dr. Johan Haggblad, Chief Scientific Officer (Age 63)
  • Mr. Mikael Widell, Head of Communications & IR (Age 63)
  • Mr. Jonathan A. Schur, Group Gen. Counsel
  • Ms. Ann-Kristin Myde, Head of Clinical Devel. & VP of Project Management (Age 66)
  • Mr. Andrew B. Udell B.Sc., M.B.A., Pres of North America (Age 51)
  • Dr. Krassimir Mitchev, Head of Medical Affairs (Age 62)
  • Dr. Richard S. Philipson M.D., Chief Medical Officer (Age 56)

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

Who are Calliditas Therapeutics AB (publ)'s major shareholders?

Calliditas Therapeutics AB (publ)'s stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%).

Which institutional investors are buying Calliditas Therapeutics AB (publ) stock?

CALT stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP.

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $19.75.

How much money does Calliditas Therapeutics AB (publ) make?

Calliditas Therapeutics AB (publ) has a market capitalization of $516.88 million and generates $90 thousand in revenue each year. The company earns $-47.25 million in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Calliditas Therapeutics AB (publ) have?

Calliditas Therapeutics AB (publ) employs 46 workers across the globe.

What is Calliditas Therapeutics AB (publ)'s official website?

The official website for Calliditas Therapeutics AB (publ) is www.calliditas.se.

Where are Calliditas Therapeutics AB (publ)'s headquarters?

Calliditas Therapeutics AB (publ) is headquartered at KUNGSBRON 1 C8, STOCKHOLM V7, 11122.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company can be reached via phone at 46-8411-3005 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.